REFERENCES
1. Menéndez R, Torres A, Aspa J, Capelastegui A, Prat C, Rodríguez de
Castro F. Neumonía adquirida en la comunidad. Nueva normativa de la
Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Arch
Bronconeumol. 2010;46:543-58.
2. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et
al. BTS guidelines for the management of community acquired pneumonia in
adults: update 2009. Thorax. 2009; 64 Suppl 3:iii1-55. [Medline]
3. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al.
Guidelines for the management of adult lower respiratory tract
infections–full version. Clin Microbiol Infect. 2011; 17 Suppl
6:E1-59.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean
NC, et al. Infectious Diseases Society of America/American Thoracic
Society consensus guidelines on the management of community-acquired
pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2:S27-72
5. Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, et
al. Diagnosis and treatment of adults with community-acquired pneumonia.
An official clinical practice guideline of the American Thoracic Society
and Infectious Diseases Society of America. Am J Respir Crit Care Med.
2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
6. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H,
Vauzelle-Kervroëdan F, et al. Low dosage and long treatment duration of
beta-lactam: risk factors for carriage of penicillin-resistant
Streptococcus pneumoniae. JAMA. 1998;279:365-70. [Medline]
7. Chalmers JD, Akram AR, Singanayagam A, Wilcox MH, Hill AT. Risk
factors for Clostridium difficile infection in hospitalized patients
with community-acquired pneumonia. J Infect. 2016;73:45-53.
[Medline]
8. Opmeer BC, El Moussaoui R, Bossuyt PM, Speelman P, Prins JM, de
Borgie CA. Costs associated with shorter duration of antibiotic therapy
in hospitalized patients with mild-to-moderate severe community-acquired
pneumonia. J Antimicrob Chemother. 2007;60:1131-6. [Medline]
9. Kardas P. Patient compliance with antibiotic treatment for
respiratory tract infections. J Antimicrob Chemother. 2002;49:897-903.
10. Moussaoui R, De Borgie CAJM, Van den Broek P, Hustinx WN, BresseR P,
Van den Berk GEL, et al. Effectiveness of discontinuing antibiotic
treatment after three days versus eight days in mild to moderate-severe
CAP: randomized,double blind study. BMJ. 2006;332:1355-8.
11. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab
MM, et al. High-dose, short-course levofloxacin for CAP: a new treatment
paradigm. Clin Infect Dis. 2003;37:752-60.
12. Ignazio D, Camere MA, Lewis DE, Jorgensen D, Breen JD. Novel,
single-dose microsphere formulation of azithromycin versus 7-day
levofloxacin therapy for treatment of mild to moderate
community-acquired pneumonia in adults. Antimicrobial Agents and
Chemotherapy. 2005;49(10)4035–41.
13. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course
antibiotic regimens for community-acquired pneumonia: A meta-analysis.
Am J Med. 2007;120(9):783-90.
14. Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, Grammatikos AP,
Athanassa Z, Falagas ME. Short- versus long-course antibacterial therapy
for community-acquired pneumonia : a meta-analysis. Drugs.
2008;68:1841-54. [Medline]
15. Tansarli GS, Mylonakis E. Systematic review and meta-analysis of the
efficacy of short-course antibiotic treatments for community-acquired
pneumonia in adults. Antimicrob Agents Chemother. 2018;62. pii:
e00635-18. doi: 10.1128/AAC.00635-18.
16. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et
al. Use of procalcitonin to reduce patients’ exposure to antibiotics in
intensive care units (PRORATA trial): a multicentre randomised
controlled trial. Lancet. 2010;375:463-74.
17. Uranga A, España PP, Bilbao A, Quintana JM, Arriaga I, Intxausti M,
et al. Duration of antibiotic treatment in community-acquired pneumonia:
a multicenter randomized clinical trial. JAMA Intern Med.
2016;176:1257-65. [Medline]
18. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify
low-risk patients with community-acquired pneumonia. New Engl J Med
1997;336:243-250.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of
classifying prognostic comorbidity in longitudinal studies: development
and validation. Chronic Dis 1987;40:373-383.
20. Katz S, Ford AB, Moskowitz R, Jackson BA, Jaffe MW. Studies of
illness in the aged: The index of ADL, a standardized measure of
biological and psychosocial function. JAMA 1963;185:914–919.
21. Lamping DL, Schroter S, Marquis P, Marrel A, Duprat-Lomon I, Sagnier
PP. The community-acquired pneumonia symptom questionnaire: a new,
patient-based outcome measure to evaluate symptoms in patients with
community-acquired pneumonia. Chest 2002;122:920-929.
22. Yi SH, Hatfield KM, Baggs J, Hicks LA, Srinivasan A, Reddy S, et al.
Duration of antibiotic use among adults with uncomplicated
community-acquired pneumonia requiring hospitalization in the United
States. Clin Infect Dis. 2018;66:1333-41.
23. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 Days of
Antibiotic Therapy for Ventilator-Associated Pneumonia in Adults. JAMA
2003;290:2588-2598.
24. Menéndez R, Méndez R, Aldás I, Reyes S, Gonzalez-Jimenez P, España
PP, et al. Community-Acquired Pneumonia Patients at Risk for Early and
Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers.
Chest 2019;156(6):1080-1091.
25. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE,
et al. Efficacy and safety of procalcitonin guidance in reducing the
duration of antibiotic treatment in critically ill patients: a
randomised, controlled, open-label trial. Lancet Infect Dis.
2016;16:819-27.
26. Kolditz M, Ewig S, Hoffken G. Management-based risk prediction in
community-acquired pneumonia by scores and biomarkers. The European
respiratory journal. 2013;41(4):974-84.
27. Bello S, Fandos S, Lasierra AB, Minchole E, Panadero C, Simon AL, et
al. Red blood cell distribution width [RDW] and long-term mortality
after community-acquired pneumonia. A comparison with proadrenomedullin.
Respiratory medicine. 2015;109(9):1193-206.
28. España PP, Capelastegui A, Mar C, Bilbao A, Quintana JM, Diez R, et
al. Performance of pro-adrenomedullin for identifying adverse outcomes
in community-acquired pneumonia. J Infect. 2015 May;70(5):457-66.
29. Uranga A, España PP. Long-term mortality in community-acquired
pneumonia. Arch Bronconeumol. 2018;54:412-3.
26. Mortensen EM. Potential causes of increased long-term mortality
after pneumonia. The European respiratory journal. 2011;37(6):1306-7.
30. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular
events in hospitalized patients with community-acquired pneumonia.
International journal of infectious diseases : IJID : official
publication of the International Society for Infectious Diseases.
2013;17(12):e1125-9.
31. Aliberti S, Ramirez JA. Cardiac diseases complicating
community-acquired pneumonia. Current opinion in infectious diseases.
2014;27(3):295-301.
32. Méndez R, Aldás I, Menéndez R.. Biomarkers in Community-Acquired
Pneumonia (Cardiac and Non-Cardiac). Review J. Clin. Med. 2020, 9(2),
549; https://doi.org/10.3390/jcm9020549